生理药代动力学模型结合瑞士HIV队列数据支持老年HIV感染者无需调整比克替拉韦剂量
本研究开发了比克替拉韦的生理药代动力学(PBPK)模型,并用瑞士HIV队列研究中的治疗药物监测(TDM)数据(年轻20-55岁与老年55-85岁HIV感染者)验证模型性能。验证后的模型预测成年期(20-99岁)比克替拉韦药代动力学的连续变化,结果显示老年与年轻感染者暴露量无差异,模拟预测暴露量随年龄增长最多增加40%,考虑安全边际,无严重合并症时老年HIV感染者无需调整剂量。
要点
- 老年与年轻HIV感染者比克替拉韦暴露量无差异。
- PBPK模拟预测成年期暴露量最多增加40%。
- 无严重合并症时老年HIV感染者无需调整剂量。
核心结论
- 结合PBPK模型与瑞士HIV队列TDM数据,老年HIV感染者使用比克替拉韦无需调整剂量。
研究设计与样本
- 基于I期临床数据开发比克替拉韦PBPK模型,并用瑞士HIV队列研究TDM数据(60名年轻和32名老年HIV感染者)验证。
主要发现
- 分析瑞士HIV队列TDM数据发现老年与年轻HIV感染者比克替拉韦暴露量无变化。
- PBPK模拟预测的浓度大多落在临床观察数据的95%置信区间内。
- 模拟预测成年期药物暴露量最多增加40%,与其他HIV及非HIV药物的年龄相关药代动力学变化无统计学显著差异。
- 性别对比克替拉韦的年龄相关药代动力学变化无影响。
关键数值与推荐
- 模拟预测成年期(20-99岁)比克替拉韦暴露量最多增加40%。
临床怎么用
- 无严重合并症的老年HIV感染者使用比克替拉韦时无需按年龄调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical studies in aging people living with HIV (PLWH) are sparse for the novel integrase inhibitor bictegravir, leading to some uncertainty about dosing recommendations for elderly PLWH. The objective of this study was to investigate the continuous impact of aging on bictegravir pharmacokinetics by combining clinically observed data with modeling to support a safe and efficient anti-HIV therapy with advanced age. A physiologically-based pharmacokinetic (PBPK) model was developed for bictegravir with clinically observed data from phase I studies. The predictive model performance was verified using bictegravir plasma concentrations sampled as part of the general therapeutic drug monitoring (TDM) program of the Swiss HIV Cohort Study in young (20-55 years) and elderly PLWH (55-85 years). The verified PBPK model subsequently predicted the continuous impact of aging on bictegravir pharmacokinetics across adulthood (20-99 years). Bictegravir exposure was unchanged in elderly compared with young PLWH when analyzing the TDM data of the Swiss HIV Cohort Study. PBPK simulations predicted clinically observed data from 60 young and 32 elderly PLWH mostly within the 95% confidence interval, demonstrating the predictive power of the used modeling approach. Simulations predicted drug exposure to increase up to 40% during adulthood, which was not statistically significantly different from the age-related pharmacokinetic changes of other HIV and non-HIV drugs. Sex had no impact on the age-related changes of bictegravir pharmacokinetics. Considering the safety margin of bictegravir, a dose adjustment for the novel integrase inhibitor is a priori not necessary in elderly PLWH in the absence of severe comorbidities.
引用
- Stader F, Courlet P, Decosterd LA, et al. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. Clin Pharmacol Ther. 2021. PMID: 33521960. doi:10.1002/cpt.2178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。